China NT Pharma Group Co (HKSE:01011) PB Ratio: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01011 China NT Pharma Group Co Ltd HKSE:01011
1 GF Score
Price HK$0.42
! 4 Warning Signs
View Full Analysis

What is China NT Pharma Group Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-02), China NT Pharma Group Co's share price is HK$0.42. China NT Pharma Group Co's Book Value per Share for the quarter that ended in Dec. 2025 was HK$-0.14. Hence, China NT Pharma Group Co's PB Ratio of today is .

The historical rank and industry rank for China NT Pharma Group Co's PB Ratio or its related term are showing as below:

During the past 13 years, China NT Pharma Group Co's highest PB Ratio was 14.46. The lowest was 0.44. And the median was 2.29.

HKSE:01011's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 31.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China NT Pharma Group Co was 63.60% per year. The lowest was -78.90% per year. And the median was -16.35% per year.

Back to Basics: PB Ratio


China NT Pharma Group Co  (HKSE:01011) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


China NT Pharma Group Co PB Ratio Related Terms


China NT Pharma Group Co PB Ratio Historical Data

* Premium members only.

The historical data trend for China NT Pharma Group Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China NT Pharma Group Co PB Ratio Chart

China NT Pharma Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China NT Pharma Group Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:01011 vs ZTS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China NT Pharma Group Co PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's PB Ratio falls into.


HKSE:01011
1GF Score
China NT Pharma Group Co Ltd HKSE:01011
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China NT Pharma Group Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

China NT Pharma Group Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.42/-0.136
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


China NT Pharma Group Co Business Description

Address 168-200 Connaught Road, Unit 2102, 21st Floor, West Tower, Shun Tak Centre, Central, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score

Get the complete analysis for HKSE:01011

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.42
Price